exRNAdisease

Entry Detail

---



General Information

Database ID: exR0274494 RNA Name: hsa-miR-130a-3p RNA Type: miRNA Chromosome: chr11 Starnd: + Coordinate: Start Site(bp): 57641252 End Site(bp): 57641273 External Links: hsa-miR-130a-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ZNF74 chr22 20394115 20408461 + E2F3 chr6 20401879 20493714 + CD151 chr11 832887 839831 + LENG8 chr19 54448887 54462037 + MTMR9 chr8 11284816 11328146 + LYSMD2 chr15 51723011 51751585 - SH3PXD2A chr10 103594027 103855543 - STK4 chr20 44966479 45080021 + STK38L chr12 27243968 27325959 + TOMM70 chr3 100363431 100401089 - G6PD chrX 154531391 154547572 - UBQLN1 chr9 83659968 83707958 - SLC12A7 chr5 1050384 1112063 - AKAP10 chr17 19904302 19978343 - STARD13 chr13 33103137 33350630 - ZBTB7B chr1 155002630 155018522 + CALU chr7 128739292 128773400 + ZNF12 chr7 6688433 6706947 - TMF1 chr3 69019827 69052339 - SNX27 chr1 151612006 151699091 + PTEN chr10 87863625 87971930 + GPRC5A chr12 12890782 12917937 + PCYOX1 chr2 70257386 70281185 + ATP6V1C1 chr8 103021063 103073051 + TRIM2 chr4 153152342 153339317 + MSTO1 chr1 155610188 155614971 + GAS2L1 chr22 29306582 29312785 + FAM102A chr9 127940582 127980989 - LIPA chr10 89213569 89414557 - PDRG1 chr20 31944337 31952046 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000591 chr15 41961025 41962156 + hsa_circ_0001454 chr4 154524454 154533552 + hsa_circ_0000384 chr12 27867712 27877119 + hsa_circ_0001723 chr7 91924202 91948826 + hsa_circ_0000892 chr19 11941431 12014514 + hsa_circ_0001605 chr6 42903447 42905047 + hsa_circ_0000155 chr1 168007608 168014465 + hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0000943 chr19 47421744 47440665 + hsa_circ_0000018 chr1 15860731 15863309 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC011503.2 chr19 23927788 23929287 + AC021092.1 chr19 44103007 44113183 - AC135050.6 chr16 31122235 31124064 + AC234582.1 chr1 155195004 155205495 + AL031595.3 chr22 44139365 44153626 + AL049840.4 chr14 103694516 103695050 - AL158206.1 chr9 19453209 19455173 + AL158825.2 chr9 75009828 75016036 - AL603839.3 chr1 40493157 40508661 - CKMT2-AS1 chr5 81201341 81301565 - H19 chr11 1995176 2001470 - HAGLR chr2 176164051 176188958 - KCNQ1OT1 chr11 2608328 2699994 - LINC01089 chr12 121795267 121803906 - MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.